News and Press Releases
Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections
Lead candidate in the ABX-01 programme to progress into first-in-human clinical studies Programme designed to treat Gram-negative bacterial lung infections in the most vulnerable patients. 4 March 2025 -- London,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
4 March 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
Mural Health and ICON Announce Partnership to Enhance Participant and Site Experience in Clinical Trials
4 March 2025 -- Pennsylvania, US and Dublin, Ireland -- Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc, a global healthcare intelligence and clinical research...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025
Allegro reports positive safety data for its injectable osteoarthritis treatment in three preclinical studies
Hydrocelin is potentially a first-in-class disease-modifying injectable treatment for osteoarthritis Pivotal clinical trial in osteoarthritis patients on track to start in 2025. 4 March 2025 -- Liege, Belgium -- Allegro...
Category: Biotechnology, Clinical Trials, Drug Delivery, Pharmaceutical
Posted: March 4, 2025
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
25 February 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: February 25, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
The Bloc Launches In.Pazienti Global Community at the 7th Patient Centricity & Collaboration World Congress
25 February 2025 -- London, UK -- Today, at the 7th Patient Centricity & Collaboration World Congress in London, The Bloc unveiled In.Pazienti, a global community that connects, supports, and...
Category: Clinical Trials, Drug Discovery, Other
Posted: February 25, 2025
ONWARD Medical Announces Publication of One-Year Study Showing Benefit of Sustained Access to ARC-EX Therapy
Study shows significant functional improvements after one year of ARC-EX Therapy Improvements were observed throughout one-year treatment period with no plateau Results demonstrate the importance of sustained access to ARC-EX...
Category: Biotechnology, Clinical Trials, Other
Posted: February 25, 2025
Bioxodes secures new funds to reach early 2025 milestones and pursue Series B financing
Bioxodes raises €2.7 million from existing investors in Series A extension Interim data from BIRCH intracerebral hemorrhage (ICH) Phase 2a trial in Q1 2025 Recruitment of up to 16 additional...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 12, 2025
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 versus...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 10, 2025
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds
7 February 2025 -- Bagsværd, Denmark -- Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 7, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded
February 04, 2025 – Berlin, Germany – Biotech Newswire / -- ProBioGen has launched its new, redesigned website to provide biotech and biopharma professionals with clear access to its expanded...
Category: Biotechnology
Posted: February 5, 2025
Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies
Bexicaserin achieved an overall median seizure reduction of 59.3 percent in countable motor seizures over a 12-month open-label extension (OLE) treatment period. The treatment with bexicaserin demonstrated favorable safety and...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2025
Phesi announces AI-driven Trial Accelerator platform hits new milestone with data from 132 million patients
Latest version of Trial Accelerator™ incorporates new AI capabilities and product features to unlock a patient-centric approach to trial design and implementation 29 January 2025 -- Boston, US -- Phesi,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2025
Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors
OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective triple inhibitor of...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 30, 2025
Rentschler Biopharma announces strategic realignment of its global business operations
30 January 2025 – Laupheim, Germany – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operations...
Category: BioManufacturing
Posted: January 30, 2025
